Hydroxylamine → 9-(Isoxazol-5-yl)-3,4,7,8-tetrahydro-[1,4]diazepino[7,1-a]isoquinoline-2,5-dione
反応式
NO.C[N:4](C)[CH:5]=[CH:6][C:7]([C:9]1[CH:18]=[CH:17][CH:16]=[C:15]2[C:10]=1[CH2:11][CH2:12][N:13]1[C:23](=[O:24])[CH2:22][NH:21][C:20](=[O:25])[CH:19]=[C:14]12)=[O:8]>CO>[O:8]1[C:7]([C:9]2[CH:18]=[CH:17][CH:16]=[C:15]3[C:10]=2[CH2:11][CH2:12][N:13]2[C:23](=[O:24])[CH2:22][NH:21][C:20](=[O:25])[CH:19]=[C:14]23)=[CH:6][CH:5]=[N:4]1参加物
4
実験手順
100-3. NH2OH*HCl (51 mg, 0.74 mmol) was added to a mixture of (E)-9-(3-(dimethylamino)acryloyl)-3,4,7,8-tetrahydro-[1,4]diazepino[7,1-a]isoquinoline-2,5-dione (160 mg, 0.49 mmol) in MeOH (5 mL) and the solution was heated to reflux for 1 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (SiO2, DCM/MeOH 99:1 to 90:10) to afford the title compound (90 mg) as a beige solid. UPLC-MS: MS 296.1 (M+H+). UPLC rt 0.65 nm.